Table 5 Summary of reported data regarding C. difficile susceptibility to MTZ, VAN, FDX, RDZ and IBZ

Dvoskin et al., 2012

(USA) [36]

Range

MIC₅₀

MIC₉₀

Not shown

2

4

N.D.

N.D.

N.D.

N.D.

Goldstein et al., 2013

Range

N.D.

0.125-0.5

0.06-1

1–8

0.25-8

(USA) [34]

MIC₅₀

MIC₉₀

0.25

0.25

0.25

0.5

1

4

0.5

2

Corbett at al., 2015

Range

N.D.

0.06–0.125

0.008–0.125

0.5-4

0.125-8

(UK) [37]

MIC₅₀

MIC₉₀

0.125

0.125

0.03

0.06

1

2

2

8

Freeman et al., 2016

Range

N.D.

0.015-0.5

0.004–0.125

0.5-8

< 0.125-2

(Europe) [38]

MIC₅₀

MIC₉₀

0.03

0.125

0.06

0.125

1

2

0.2

2

Snydman et al., 2017

Range

N.D.

0.12–0.5

0.015-1

0.25-4

0.12-2

(US) [39]

MIC₅₀

MIC₉₀

0.12

0.25

0.03

0.125

1

2

0.25

1

Snydman et al., 2018

*Range

N.D.

0.06–0.5

0.06-1

1–4

0.12-4

(US) [11]

MIC₅₀

MIC₉₀

0.12

0.25

0.12

0.5

1

2

0.5

2

#Range

0.06–0.5

0.06-1

0.5-2

0.12-2

MIC₅₀

MIC₉₀

0.12

0.5

0.25

0.5

1

2

0.25

1

van Eijk, et al., 2019 (the Netherlands) [33]

Range

MIC₅₀

MIC₉₀

0.5-4

2

4

N.D.

N.D.

N.D.

N.D.

Murray et al., 2020 (USA) [14]

Range

MIC₅₀

MIC₉₀

1–8

4

4

N.D.

0.015-1

0.12

0.25

0.5-4

1

2

0.25-16

0.5

1

Collins et al., 2021

(Japan, China, South Korea) [30]

Range

N.D.

0.03–0.25

0.125

0.25

0.015–0.25

0.125

0.25

0.06-4

1

2

0.06–0.5

0.25

0.25

MIC₅₀

MIC₉₀

Snydman et al., 2023

Range

N.D.

0.3–0.5

0.03–0.5

0.25-4

0.12-4

(US) [29]

MIC₅₀

MIC₉₀

0.25

0.25

0.25

0.5

2

2

0.5

1

Bassères et al., 2024

(US) [32]

Range

MIC₅₀

MIC₉₀

-

4

8

N.D.

-

0.5

1

-

2

4

-

0.25

4

The current study

Range

0.5-8

0.06–0.5

0.03-16

0.064-256

0.016-256

(Israel)

MIC₅₀

MIC₉₀

4

4

0.25

0.5

0.25

0.5

0.5

0.75

0.19

0.38